ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Short DAPT Wins, Ultra-Short Fails 🚫1️⃣✅3️⃣ Stratified Strategy From HOST-BR"
Episode Synopsis
🫀 Personalizing DAPT: When "One Size Fits All" Fails 🕊️💊 The HOST-BR trial in The Lancet offers an important clinical lesson: Bleeding risk should guide antiplatelet duration after PCI — not habit, not inertia. 🔍 Key insight In ARC-HBR patients, 1-month DAPT was not non-inferior to 3 months In non-HBR patients, 3-month DAPT was non-inferior to 12 months and reduced bleeding 🧠 Clinical takeaway ➡️ Ultra-short (1-mo) DAPT is risky in high-bleeding-risk patients ➡️ Short (3-mo) DAPT is safe and bleeding-sparing in lower-risk patients 🔧 Precision medicine in action: Stratify → Tailor → Protect 📎 HOST-BR | The Lancet (2025) A beautiful reminder that medicine advances when we match therapy to physiology — not the other way around. 🌟 "Do no harm" is evolving… now it means do no unnecessary bleeding. #Cardiology #InterventionalCardiology #PrecisionMedicine #DAPT #PCI #BleedingRisk #Lancet
In God we trust